Non‐D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles?

Kitazawa, Junichi; Nollet, Kenneth E.; Morioka, Hiroyuki; Tanaka, Kazuto; Inomata, Makiko; Kubuki, Youko; Ohto, Hitoshi

doi:10.1111/j.1423-0410.2010.01435.x

Cited by 30 publications

(31 citation statements)

References 11 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are concordant with recent data published by Kitazawa et al [70] who stained RBCs and PLTs in the PLT samples with anti-glycophorin A and anti-CD41 to count residual RBCs and residual RBC derived microparticles. Microparticles are cell derived membrane vesicles that range in size between 0.1 and 1 µm [71] and express D antigen on their surface, if they are obtained from a D+ donor [72].…”

Section: Part 2: Plt Transfusion and The D Antigensupporting

confidence: 83%

“…However, as stated before, recent data from Kitazawa et al [70] showed that PLTs collected by apheresis contained a residual RBC volume and RBC-derived microparticle volume in the range of 0.4-0.8 µl and 0.1-1 µl, respectively. On a per-volume basis, these potential antigenic stimuli matched to within an order of magnitude, but the authors hypothesized that the smaller, more numerous RBC derived microparticles may be more immunogenic than RBCs themselves, because they could easily be phagocytosed by recipient antigen presenting cells.…”

Section: Part 2: Plt Transfusion and The D Antigenmentioning

confidence: 96%

“…Microparticles are cell derived membrane vesicles that range in size between 0.1 and 1 µm [71] and express D antigen on their surface, if they are obtained from a D+ donor [72]. These authors estimated that PLTs collected by apheresis contained a residual RBC volume and RBC derived microparticle volume in the range of 0.0004-0,0008 ml and 0.0001-0,001 ml, respectively [70]. …”

Section: Part 2: Plt Transfusion and The D Antigenmentioning

confidence: 99%

“…On a per-volume basis, these potential antigenic stimuli matched to within an order of magnitude, but the authors hypothesized that the smaller, more numerous RBC derived microparticles may be more immunogenic than RBCs themselves, because they could easily be phagocytosed by recipient antigen presenting cells. However, the authors concluded that the alloimmunization potential of such a small volume of RBC derived microparticles was theoretical, but their existence would require further research aimed at minimizing the immunological side effects associated with their transfusion [70]. …”

Section: Part 2: Plt Transfusion and The D Antigenmentioning

confidence: 99%

See 3 more Smart Citations

Platelet Transfusion - the Art and Science of Compromise

Cid

Harm

Yazer

2013

Transfus Med Hemother

View full text Add to dashboard Cite

Many modern therapies depend on platelet (PLT) transfusion support. PLTs have a 4- to 7-day shelf life and are frequently in short supply. In order to optimize the inventory PLTs are often transfused to adults without regard for ABO compatibility. Hemolytic reactions are infrequent despite the presence of ‘high titer' anti-A and anti-B antibodies in some of the units. Despite the low risk for hemolysis, some centers provide only ABO identical PLTs to their recipients; this practice might have other beneficial outcomes that remain to be proven. Strategies to mitigate the risk of hemolysis and the clinical and laboratory outcomes following ABO-matched and mismatched transfusions will be discussed. Although the PLTs themselves do not carry the D antigen, a small number of RBCs are also transfused with every PLT dose. The quantity of RBCs varies by the type of PLT preparation, and even a small quantity of D+ RBCs can alloimmunize a susceptible D- host. Thus PLT units are labeled as D+/-, and most transfusion services try to prevent the transfusion of D+ PLTs to D- females of childbearing age. A similar policy for patients with hematological diseases is controversial, and the elements and mechanisms of anti-D alloimmunization will be discussed.

show abstract

Section: Part 2: Plt Transfusion and The D Antigensupporting

confidence: 83%

Section: Part 2: Plt Transfusion and The D Antigenmentioning

confidence: 96%

Section: Part 2: Plt Transfusion and The D Antigenmentioning

confidence: 99%

Section: Part 2: Plt Transfusion and The D Antigenmentioning

confidence: 99%

See 2 more Smart Citations

Platelet Transfusion - the Art and Science of Compromise

Cid

Harm

Yazer

2013

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…In contrast to this study, Villalba et al [9] and Reckhaus et al [10] presented data from RhD-different platelet (PLT) transfusions. Villalba et al retrospectively studied the formation of anti-D in a group of 48 RhD-female leukemia patients below 55 years of age (roughly 'childbearing age' and Heuft/Mansouri Taleghani Transfus Med Hemother 2018;45:148-150 150 [20] hypothesized that RBC microparticles could contribute to RBC alloimmunization. Microparticles can be phagocytosed and therefore could be as immunogenic as RBC.…”

mentioning

confidence: 99%

Hemovigilance

Heuft

Taleghani

2018

Transfus Med Hemother

View full text Add to dashboard Cite

Rh Sensitization and Induced Abortion

Moise,

Abels

2024

JAMA

View full text Add to dashboard Cite

In Reply We thank Dr Hecht for his comment on our recent research article examining sedentary behavior and incident dementia. 1 We agree that the possibility of ascertainment bias is an important issue that warrants careful consideration. As we discussed in the Limitations section of our article, 1 the use of hospital records and death registry data for dementia diagnoses may provide less accurate diagnoses or may underestimate cases in this cohort, leading to the potential for ascertainment bias related to links between physical activity and overall health. To help address this limitation, we included presence of chronic disease (cardiovascular disease, cancer, or diabetes) as well as self-reported general health in our fully adjusted models to account for health conditions other than dementia in this sample. 1 To further determine whether the likelihood of hospitalization or death impacts our results, we have now included the number of hospitalizations after the start of follow-up, as well as death events, as additional covariates in our fully adjusted model. Inclusion of these covariates did not substantially affect our results showing that sedentary behavior has a nonlinear association with incident dementia; however, the hazard ratios for dementia were somewhat attenuated. In a model including these new covariates, hazard ratios for dementia relative to median sedentary behavior (9.27 hours per day) were 1.06 (95% CI, 1.02-1.10; P < .01) for 10 hours per day, 1.46 (95% CI, 1.22-1.76; P < .001) for 12 hours per day, and 2.51 (95% CI, 1.61-3.92; P < .001) for 15 hours per day. In a second analysis, we restricted our sample to only individuals with a hospital record or who died during follow-up. Again, results were similar to our original findings: hazard ratios for dementia relative to median sedentary behavior (9.27 hours per day) were 1.06 (95% CI, 1.01-1.11; P = .03) for 10 hours per day, 1.40 (95% CI, 1.08-1.80; P = .01) for 12 hours per day, and 2.21 (95% CI, 1.20-4.08; P = .01) for 15 hours per day. While these analyses cannot fully rule out the possibility of ascertainment bias, we believe our original results controlling for health status, combined with these new analyses controlling for hospitalizations and death, further support our overall finding that engaging in large amounts of sedentary behavior is associated with greater risk of dementia. Future work that can include other sources of information for dementia diagnoses will allow us to further test the association between sedentary behavior and all-cause dementia.

show abstract

Non‐D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles?

Cited by 30 publications

References 11 publications

Platelet Transfusion - the Art and Science of Compromise

Platelet Transfusion - the Art and Science of Compromise

Hemovigilance

Rh Sensitization and Induced Abortion

Contact Info

Product

Resources

About